PedAM
Pediatric Disease Annotations & Medicines
| Disease | myelodysplastic syndrome |
| Phenotype | C0002871|anemia |
| Sentences | 35 |
| PubMedID- 20367566 | Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life. |
| PubMedID- 24958999 | Proteome changes in the plasma of myelodysplastic syndrome patients with refractory anemia with excess blasts subtype 2. |
| PubMedID- 23690786 | The patient's medical history revealed that he was suffering from myelodysplastic syndrome, complicated by autoimmune hemolytic anemia since march 2012, treated with periodic blood transfusions, alpha recombinant human erythropoietin 40,000 iu/week subcutaneously, and since the last month, with prednisone 25 mg/day, cutting down the dosage by half every week. |
| PubMedID- 23358617 | Darbepoetin (dar), with or without granulocyte colony-stimulating factor (g-csf), has proved effective in treating anemia in patients with lower-risk myelodysplastic syndrome (mds), but its effects on quality of life (qol) and exercise functioning are less well established. |
| PubMedID- 25485173 | Background: erythropoiesis-stimulating agents (esas) are widely used to treat anemia associated with myelodysplastic syndromes (mds) as an off-label indication. |
| PubMedID- 21338284 | Lenalidomide is approved for use in low/intermediate-1 risk myelodysplastic syndromes associated with transfusion-dependent anemia and a deletion 5q cytogenetic abnormality and, in combination with dexamethasone, in relapsed myeloma. |
| PubMedID- 21381892 | Background: current guidelines support the use of erythropoiesis-stimulating agents for the treatment of anemia associated with low-risk myelodysplastic syndromes (mds). |
| PubMedID- 21625998 | Very short-term lenalidomide treatment associated with durable resolution of anemia in a patient with myelodysplastic syndrome with chromosome 5q deletion. |
| PubMedID- 25579702 | Darbepoetin alfa for anemia with myelodysplastic syndrome. |
| PubMedID- 26171179 | The aim of this the study was to verify that biosimilar epoetin-alpha is similar in terms of efficacy, safety and cost to originator epoetin-alpha for the treatment of refractory anemia in patients with myelodysplastic syndrome. |
| PubMedID- 22584540 | Copper deficiency manifested in all of our patients as either microcytic anemia or pancytopenia with myelodysplastic syndrome. |
| PubMedID- 26264606 | Hematologic disorders included chronic myeloic leukemia, juvenile myelo-monocytic leukemia, lymphoblastic leukemia, sideroblastic anemia and two cases of myelodysplastic syndrome (mds). |
| PubMedID- 25638763 | Patients who were not treated exclusively in the hematology and oncology service, hc-ufpr were excluded as were those who had biphenotypic leukemia, fanconi anemia either associated with myelodysplastic syndrome or in isolation, those who were diagnosed before 2003 and those whose medical records were not available. |
| PubMedID- 24627811 | Her past medical history was significant for atrial fibrillation, hypertension, diabetes mellitus, coronary artery disease, cardiomyopathy, hypothyroidism, myelodysplastic syndrome with chronic anemia, cerebrovascular accident, chronic kidney disease, peptic ulcer disease, peripheral vascular disease, and pulmonary hypertension. |
| PubMedID- 23523473 | Erythropoiesis-stimulating agents (esa) are used commonly to reduce symptomatic anemia in patients with myelodysplastic syndromes (mds). |
| PubMedID- 25563701 | Erythropoiesis-stimulating agents (esas) used for chronic anemia management in patients with myelodysplastic syndromes (mds) are commonly injected in a physician office but can be administered safely at home. |
| PubMedID- 20569983 | We performed an open-labeled single-arm prospective phase ii clinical trial of vitamin k(2) (menatetrenone: vk2) monotherapy and vk2 plus 1alpha-hydroxyvitamin d(3) (alfacalcidol: vd3) combination therapy for myelodysplastic syndromes (mds) with refractory anemia and refractory cytopenia with multilineage dysplasia, having either low or intermediate-1 risks of the ipss. |
| PubMedID- 24675455 | Patients affected by myelodysplastic syndromes (mds) with transfusion-dependent anemia are destined to develop iron overload. |
| PubMedID- 22934211 | Our patient has a long-standing history of clonal (5q minus) myelodysplastic syndrome associated with refractory normocytic anemia and small hypolobated megakaryocytes. |
| PubMedID- 22550403 | Only six cases of leukemia/myelodysplastic syndrome were identified in patients with sickle cell anemia treated with hydroxyurea. |
| PubMedID- 25018950 | If at all esa responsive, the anemia in patients with myelodysplastic syndrome responds more slowly. |
| PubMedID- 26379438 | Background: lenalidomide is approved for treating transfusion-dependent anemia due to lower-risk del(5q) myelodysplastic syndromes (mds). |
| PubMedID- 22525275 | Allelic deletion of the rps14 gene is a key effector of the hypoplastic anemia in patients with myelodysplastic syndrome (mds) and chromosome 5q deletion (del(5q)). |
| PubMedID- 23897263 | Correlation between dysplastic lineage and type of cytopenia in myelodysplastic syndromes patients with refractory anemia according to the fab classification. |
| PubMedID- 24716056 | Final diagnosis was high-grade myelodysplastic syndrome consistent with refractory anemia with excess blasts. |
| PubMedID- 20052416 | When we examined chk1 expression in this data set, we found it significantly decreased in patients suffering from myelodysplastic syndromes with refractory anemia with blasts [29] (figure 7b). |
| PubMedID- 20037898 | The findings were diagnostic of myelodysplastic syndrome with refractory anemia with excess of blasts in accordance with the world health organization criteria modified for pediatric age group. |
| PubMedID- 20809214 | Epo+gcsf combination therapy has proven useful in the treatment of patients with refractory anemia due to myelodysplastic syndrome by a synergistic inhibition of progenitor cell apoptosis, [36] and possibly by enhancement of stem cell mobilization [37]. |
| PubMedID- 23316859 | This drug has been approved by the food and drug administration for transfusion-dependent anemia due to low-risk myelodysplastic syndromes (mds) associated with deletion 5q abnormality with or without additional cytogenetic abnormalities and multiple myeloma in combination with dexamethasone. |
| PubMedID- 21434945 | In many patients with refractory anemia associated with lower risk myelodysplastic syndromes and a 5q chromosome deletion, lenalidomide leads to transfusion independence, considerably improving quality of life. |
| PubMedID- 20485382 | Nearly all patients develop aplastic anemia, and nearly half of patients develop myelodysplastic syndrome or acute myeloid leukemia. |
| PubMedID- 21226301 | An 85-year-old woman, who had been given a diagnosis of myelodysplastic syndrome with refractory anemia 2 years previously and required blood transfusion once a month, was admitted with complaints of fever, general fatigue, and dry cough. |
| PubMedID- 25428262 | The splicing factor sf3b1 is the most commonly mutated gene in the myelodysplastic syndrome (mds), particularly in patients with refractory anemia with ring sideroblasts (rars). |
| PubMedID- 26493409 | Since the patient refused bone marrow evaluation, she was initially treated with erythropoietin therapy based on the assumption that she may have an underlying refractory anemia associated with myelodysplastic syndrome or anemia of chronic disease. |
| PubMedID- 25971272 | [cold autoimmune hemolytic anemia complicated with relapsed myelodysplastic syndrome after allogeneic hematopoietic cell transplantation]. |
Page: 1